Evidence map›Paper›PMID 39651238›Full record

ArticlebioRxiv : the preprint server for biology2025

Evolutionary rescue model informs strategies for driving cancer cell populations to extinction.

Amjad Dabi, Joel S Brown, Robert A Gatenby, Corbin D Jones, Daniel R Schrider

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Amjad DabiDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0002-7259-4608
Joel S BrownDepartment of Cancer Biology and Evolution, Moffitt Cancer Center, Tampa, FL, USA.
Robert A GatenbyDepartment of Cancer Biology and Evolution, Moffitt Cancer Center, Tampa, FL, USA.
Corbin D JonesDepartment of Biology, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0001-7281-7130
Daniel R SchriderDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0001-5249-4151

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Advancing evolutionary genetics through deep learningR35GM138286 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DANIEL R SCHRIDER · 2020 to 2026
$2.8M
NCI NIH HHS P30 CA016086NIGMS NIH HHS R35 GM138286
6 · The paper itself

Abstract

Cancers exhibit a remarkable ability to develop resistance to a range of treatments, often resulting in relapse following first-line therapies and significantly worse outcomes for subsequent treatments. While our understanding of the mechanisms and dynamics of the emergence of resistance during cancer therapy continues to advance, questions remain about how to minimize the probability that resistance will evolve, thereby improving long-term patient outcomes. Here, we present an evolutionary simulation model of a clonal population of cells that can acquire resistance mutations to one or more treatments. We leverage this model to examine the efficacy of a two-strike "extinction therapy" protocol, in which two treatments are applied sequentially to first contract the population to a vulnerable state and then push it to extinction, and compare it to a combination therapy protocol. We investigate how factors such as the timing of the switch between the two strikes, the rate of emergence of resistant mutations, the doses of the applied drugs, the presence of cross-resistance, and whether resistance is a binary or a quantitative trait affect the outcome. Our results show that the timing of switching to the second strike has a marked effect on the likelihood of driving the cancer to extinction, and that extinction therapy outperforms combination therapy when cross-resistance is present. We conduct an

Identifiers

PMID39651238
PMCPMC11623570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.